ReviewCurrent opinion in nephrology and hypertension2019
Unmet challenges in membranous nephropathy.
Review in Current opinion in nephrology and hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Secondary Membranous Nephropathy. A Narrative Review.Frontiers in medicine · 2020Pooled it
- A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLABMC nephrology · 2024Trial
- The correlation of anti-β2-glycoprotein I antibody with complement activation in patients with idiopathic membranous nephropathy.International urology and nephrology · 2021Trial
- Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.Renal failure · 2020Trial
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- Antibody-induced internalization and degradation of PLA2R amplifies CD4Theranostics · 2026Article
- Narrative review on decoding the crosstalk between lipid homeostasis and immune pathways in membranous nephropathy.BMC nephrology · 2025Review
- THSD7A as a Promising Biomarker for Membranous Nephrosis.Molecular biotechnology · 2024Review
- Membranous nephropathy: pathogenesis and treatments.MedComm · 2024Review
- Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.Drugs · 2023Review
- Primary membranous nephropathy: an endless story.Journal of nephrology · 2023Review
- Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.Frontiers in immunology · 2022Review
- Lupus Membranous Nephropathy.Glomerular diseases · 2021Review
- Establishing a Case for Anti-complement Therapy in Membranous Nephropathy.Kidney international reports · 2021Article
- Anti-Neuronal IgG4 Autoimmune Diseases and IgG4-Related Diseases May Not Be Part of the Same Spectrum: A Comparative Study.Frontiers in immunology · 2021Article
- Chylomicronemia from GPIHBP1 autoantibodies.Journal of lipid research · 2020Review
- Mitochondrial dysfunction in kidney injury, inflammation, and disease: Potential therapeutic approaches.Kidney research and clinical practice · 2020Review
- Advances in Pathogenesis of Idiopathic Membranous Nephropathy.Kidney diseases (Basel, Switzerland) · 2020Review
- Proteomic Analysis of Complement Proteins in Membranous Nephropathy.Kidney international reports · 2020Article
- Advances of the experimental models of idiopathic membranous nephropathy (Review).Molecular medicine reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewDespite major advances in since the discovery of the phospholipase A2 receptor (PLA2R) as the major autoantigen on podocytes in primary membranous nephropathy, there are still several unanswered questions as highlighted here. RECENT
findingsA substantial body of literature, included in more than 680 articles since 2009, has documented genetic susceptibility to primary membranous nephropathy involving PLA2R1 and class II MHC alleles, the clinical value of anti-PLA2R assays, the significance of epitope spreading of the anti-PLA2R response, discovery of thrombospondin type I domain-containing 7A (THSD7A) as a minor antigen in primary membranous nephropathy, and the ability to transfer disease into mice by infusion of anti-THSD7A sera. However, the normal physiology and pathophysiology of PLA2R and THSD7A in podocytes is still unknown and the genetic influence on disease susceptibility is unexplained. We still do not know what causes loss of self-tolerance to PLA2R and THSD7A or how the autoantibodies, which are predominantly of the IgG4 subclass, cause podocyte injury and proteinuria. Complement deposits are prominent in membranous nephropathy but we are still uncertain how the complement system is activated and whether or not it plays a role in podocyte damage. Notwithstanding the advances over the past decade, our treatments have not changed substantially. SUMMARY: This review identifies opportunities to extend the advances that have been made to better understand the immunopathogenesis and genetic basis of primary membranous nephropathy and apply the knowledge to design more specific therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.